BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23061804)

  • 1. Ruxolitinib: in the treatment of myelofibrosis.
    Yang LP; Keating GM
    Drugs; 2012 Nov; 72(16):2117-27. PubMed ID: 23061804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
    Martí-Carvajal AJ; Anand V; Solà I
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
    N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib: a review of its use in patients with myelofibrosis.
    Plosker GL
    Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
    Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
    Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
    Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
    J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib for the treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Drugs Today (Barc); 2011 Nov; 47(11):817-27. PubMed ID: 22146225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
    Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
    Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
    Vannucchi AM; Kantarjian HM; Kiladjian JJ; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P; Hmissi A; Stalbovskaya V; Gupta V; Harrison C; Verstovsek S;
    Haematologica; 2015 Sep; 100(9):1139-45. PubMed ID: 26069290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
    Ostojic A; Vrhovac R; Verstovsek S
    Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
    J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
    Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.
    Wade R; Rose M; Neilson AR; Stirk L; Rodriguez-Lopez R; Bowen D; Craig D; Woolacott N
    Pharmacoeconomics; 2013 Oct; 31(10):841-52. PubMed ID: 23996108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.